Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Rhabdomyosarcoma 5Prostatic Neoplasms 5Sarcoma, Synovial 3Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma, Ewing 2Neoplasm Metastasis 2Lung Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Head and Neck Neoplasms 2Fibrosarcoma 2Colorectal Neoplasms 2Adrenocortical Carcinoma 2Zollinger-Ellison Syndrome 1Wilms Tumor 1Uveal Melanoma 1Unspecified Childhood Solid Tumor, Protocol Specific 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Pinealoma 1

Interventions

vandetanib 14cabozantinib 9selpercatinib 6Sorafenib 5Everolimus 5pralsetinib 3Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Thyroidectomy 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × cixutumumab × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡